Coultreon secures $125M Series A to advance oral immune drug into Phase 2 trials

Coultreon Biopharma announced a $125 million Series A financing round to fund development of an oral drug it licensed from Galapagos.

The round was led by Sofinnova Investments and included nine investors such as Forbion, Novo Holdings, Galapagos and Regeneron’s venture arm.

The capital will move the drug, identified as COL-5671, from Phase 1 into Phase 2 studies targeting psoriasis and ulcerative colitis, with early data expected in 2027.

Coultreon, formerly Onco3R Therapeutics, aims to provide alternatives to injectable biologics for autoimmune diseases, citing unmet needs for durable disease control.